|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLYWCH1 |
Gene summary for FLYWCH1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLYWCH1 | Gene ID | 84256 |
| Gene name | FLYWCH-type zinc finger 1 | |
| Gene Alias | FLYWCH1 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q4VC44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84256 | FLYWCH1 | LZE4T | Human | Esophagus | ESCC | 9.14e-05 | 1.67e-01 | 0.0811 |
| 84256 | FLYWCH1 | LZE8T | Human | Esophagus | ESCC | 2.50e-02 | 8.74e-02 | 0.067 |
| 84256 | FLYWCH1 | LZE24T | Human | Esophagus | ESCC | 1.46e-07 | 2.84e-01 | 0.0596 |
| 84256 | FLYWCH1 | P1T-E | Human | Esophagus | ESCC | 2.18e-02 | 2.68e-01 | 0.0875 |
| 84256 | FLYWCH1 | P2T-E | Human | Esophagus | ESCC | 1.06e-25 | 4.55e-01 | 0.1177 |
| 84256 | FLYWCH1 | P4T-E | Human | Esophagus | ESCC | 1.68e-09 | 2.64e-01 | 0.1323 |
| 84256 | FLYWCH1 | P5T-E | Human | Esophagus | ESCC | 1.55e-06 | 1.07e-01 | 0.1327 |
| 84256 | FLYWCH1 | P8T-E | Human | Esophagus | ESCC | 6.64e-03 | 6.28e-02 | 0.0889 |
| 84256 | FLYWCH1 | P9T-E | Human | Esophagus | ESCC | 2.45e-07 | 1.82e-01 | 0.1131 |
| 84256 | FLYWCH1 | P10T-E | Human | Esophagus | ESCC | 7.34e-04 | 4.22e-02 | 0.116 |
| 84256 | FLYWCH1 | P11T-E | Human | Esophagus | ESCC | 1.72e-13 | 5.96e-01 | 0.1426 |
| 84256 | FLYWCH1 | P12T-E | Human | Esophagus | ESCC | 2.50e-18 | 3.12e-01 | 0.1122 |
| 84256 | FLYWCH1 | P15T-E | Human | Esophagus | ESCC | 1.67e-17 | 4.07e-01 | 0.1149 |
| 84256 | FLYWCH1 | P16T-E | Human | Esophagus | ESCC | 2.08e-10 | 7.45e-02 | 0.1153 |
| 84256 | FLYWCH1 | P17T-E | Human | Esophagus | ESCC | 1.27e-03 | 2.08e-01 | 0.1278 |
| 84256 | FLYWCH1 | P20T-E | Human | Esophagus | ESCC | 9.30e-10 | 2.62e-01 | 0.1124 |
| 84256 | FLYWCH1 | P21T-E | Human | Esophagus | ESCC | 7.34e-11 | 2.06e-01 | 0.1617 |
| 84256 | FLYWCH1 | P22T-E | Human | Esophagus | ESCC | 1.18e-14 | 1.64e-01 | 0.1236 |
| 84256 | FLYWCH1 | P23T-E | Human | Esophagus | ESCC | 8.74e-04 | 1.69e-01 | 0.108 |
| 84256 | FLYWCH1 | P24T-E | Human | Esophagus | ESCC | 3.46e-04 | 1.14e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLYWCH1 | SNV | Missense_Mutation | novel | c.303N>C | p.Gln101His | p.Q101H | Q4VC44 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FLYWCH1 | SNV | Missense_Mutation | c.1811N>T | p.Ser604Phe | p.S604F | Q4VC44 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| FLYWCH1 | SNV | Missense_Mutation | rs371092849 | c.814N>A | p.Glu272Lys | p.E272K | Q4VC44 | protein_coding | deleterious(0.05) | probably_damaging(0.959) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
| FLYWCH1 | SNV | Missense_Mutation | c.2092N>A | p.Glu698Lys | p.E698K | Q4VC44 | protein_coding | tolerated_low_confidence(0.06) | possibly_damaging(0.636) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| FLYWCH1 | SNV | Missense_Mutation | novel | c.1780N>A | p.Pro594Thr | p.P594T | Q4VC44 | protein_coding | tolerated(0.38) | benign(0.003) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| FLYWCH1 | SNV | Missense_Mutation | rs766048567 | c.1615N>C | p.Thr539Pro | p.T539P | Q4VC44 | protein_coding | deleterious(0.05) | probably_damaging(0.995) | TCGA-S3-A6ZG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
| FLYWCH1 | deletion | Frame_Shift_Del | c.1278delN | p.Gly428AlafsTer44 | p.G428Afs*44 | Q4VC44 | protein_coding | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| FLYWCH1 | SNV | Missense_Mutation | rs747935316 | c.1408C>T | p.Arg470Trp | p.R470W | Q4VC44 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FLYWCH1 | SNV | Missense_Mutation | rs866521894 | c.1960C>T | p.Arg654Cys | p.R654C | Q4VC44 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FLYWCH1 | SNV | Missense_Mutation | rs780119016 | c.1688N>A | p.Arg563His | p.R563H | Q4VC44 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |